Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Prodia Widyahusada TbkPRWDF 74 Future 3-5Y EPS without NRI Growth Rate is 12.50 as of Sep. 09, 2026. GuruFocus rates PRWDF with a GF Score™ of 74/100. The stock has 1 warning sign investors should review. Among 64 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks worse than 65.63% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
PT Prodia Widyahusada Tbk Future 3-5Y EPS without NRI Growth Rate Related Terms
PRWDF vs TMO, DHR, NTRA: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk Future 3-5Y EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 12.50 mean?
PT Prodia Widyahusada Tbk (PRWDF) has a Future 3-5Y EPS without NRI Growth Rate of 12.50 as of Sep. 09, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for PT Prodia Widyahusada Tbk and its competitors. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #42 out of 64 companies in the Medical Diagnostics & Research industry, placing it in the top 65.6%.
Is PT Prodia Widyahusada Tbk's Future 3-5Y EPS without NRI Growth Rate too high?
PT Prodia Widyahusada Tbk's current Future 3-5Y EPS without NRI Growth Rate is 12.50. The Medical Diagnostics & Research industry median Future 3-5Y EPS without NRI Growth Rate is 17.57. PT Prodia Widyahusada Tbk's value of 12.50 is 28.9% below this industry median. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #42 out of 64 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's Future 3-5Y EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #42 out of 64 companies for Future 3-5Y EPS without NRI Growth Rate. This places PT Prodia Widyahusada Tbk in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.57. PT Prodia Widyahusada Tbk's value of 12.50 is 28.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 17.57, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Prodia Widyahusada Tbk's current Future 3-5Y EPS without NRI Growth Rate of 12.50 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for PT Prodia Widyahusada Tbk and its competitors. For the Medical Diagnostics & Research industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current Future 3-5Y EPS without NRI Growth Rate is 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current Future 3-5Y EPS without NRI Growth Rate of 12.50. The current Future 3-5Y EPS without NRI Growth Rate is 12.50 and 28.9% below the Medical Diagnostics & Research industry median of 17.57. PT Prodia Widyahusada Tbk's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current Future 3-5Y EPS without NRI Growth Rate is 12.50 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 
